Assessing the impact of hemodynamic monitoring with CardioMEMS on heart failure patients: A cost-effectiveness analysis

被引：0
|
作者：
Andrea Carrete, A. [1 ]
Codina, P. [1 ]
Vicente Gomez, J. A. [1 ]
Hernandez Guillamet, G. [1 ]
Ricou Rios, L. [1 ]
Vilalta, V. [1 ]
Estrada, O. [1 ]
Ara, J. [1 ]
Santiago-Vacas, E. [1 ]
Cediel, G. [1 ]
Borrellas, A. [1 ]
Domingo, M. [1 ]
Lupon, J. [1 ]
Bayes-Genis, A. [1 ]
Segui, F. Lopez [1 ]
机构：
[1] Univ Hosp Germans Trias & Pujol Badalona, Badalona, Spain
来源：
EUROPEAN JOURNAL OF HEART FAILURE | 2023年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：428 / 429
页数：2
相关论文
共 50 条
  • [41] From cost of illness to cost-effectiveness in heart failure
    Lévy, E
    EUROPEAN HEART JOURNAL, 1998, 19 : P2 - P4
  • [42] Cost and cost-effectiveness studies in heart failure research
    Weintraub, WS
    Cole, J
    Tooley, JF
    AMERICAN HEART JOURNAL, 2002, 143 (04) : 565 - 576
  • [43] A MODEL-BASED COST-EFFECTIVENESS ANALYSIS OF B-TYPE NATRIURETIC PEPTIDE MONITORING IN PATIENTS WITH HEART FAILURE
    Mohiuddin, S.
    Hollingworth, W.
    Maishman, R.
    Dayer, M.
    MacLeod, J.
    McDonagh, T.
    Purdy, S.
    Reeves, B.
    Rogers, C.
    Pufulete, M.
    VALUE IN HEALTH, 2016, 19 (07) : A867 - A867
  • [44] Real-world eligibility and cost-effectiveness analysis for empagliflozin in patients with heart failure
    Kim, E. S.
    Park, S. K.
    Youn, J. C.
    EUROPEAN HEART JOURNAL, 2022, 43 : 972 - 972
  • [45] Cost-Effectiveness Analysis of Sacubitril/Valsartan Compared to Enalapril for Heart Failure Patients in Indonesia
    Zakiyah, Neily
    Sinuraya, Rano K.
    Kusuma, Arif S. W.
    Suwantika, Auliya
    Lestari, Keri
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2021, 13 : 863 - 872
  • [46] Correction to: Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia
    Mark Bounthavong
    Javed Butler
    Chantal M. Dolan
    Jeffrey D. Dunn
    Kathryn A. Fisher
    Nina Oestreicher
    Bertram Pitt
    Paul J. Hauptman
    David L. Veenstra
    PharmacoEconomics, 2019, 37 : 1071 - 1071
  • [47] Real-World Eligibility and Cost-Effectiveness Analysis for Empagliflozin in Patients with Heart Failure
    Kim, E.
    Kim, K.
    Park, S.
    Youn, J.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2023, 42 (04): : S82 - S82
  • [48] Cost-Effectiveness Ratio Analysis of LBBaP Versus BVP in Heart Failure Patients With LBBB
    Wang, Shengchan
    Xue, Siyuan
    Jiang, Zhixin
    Hou, Xiaofeng
    Zou, Fengwei
    Yang, Wen
    Zhou, Xiujuan
    Zhang, Shigeng
    Zou, Jiangang
    Shan, Qijun
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2024, 47 (11): : 1539 - 1547
  • [49] Ferric carboxymaltose for patients with heart failure and iron deficiency in Italy: cost-effectiveness and budget impact
    Rognoni, Carla
    Gerzeli, Simone
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2019, 8 (13) : 1099 - 1110
  • [50] Cost-Effectiveness of Implantable Pulmonary Artery Pressure Monitoring in Chronic Heart Failure
    Sandhu, Alexander T.
    Goldhaber-Fiebert, Jeremy D.
    Owens, Douglas K.
    Turakhia, Mintu P.
    Kaiser, Daniel W.
    Heidenreich, Paul A.
    JACC-HEART FAILURE, 2016, 4 (05) : 368 - 375
12345